Reagents, Reference Materials & Laboratory Chemicals
New IRMS standards expands analytical capabilities
Elemental Microanalysis, a leading global supplier to the elemental analysis market, is pleased to announce the release of five additional IRMS standards.
Elemental’s R&D development expert in isotopic ratio mass spectrometry, David Castle, and his team, have brought five IRMS reference material standards to market: an additional caffeine, two glucose, and two gelatin IRMS. This analyser calibration offering expands Elemental’s isotope reference material range to a total of 26 products, including: wheat flour, sorghum flour, olive oil, silver phosphate, and water.
The two glucose standards are derived from differing plant types, wheat (B2217, a C3 type) and cane sugar (B2218, a C4 type), to provide different 13C values, offering two anchor points for simple carbon isotope analysis.
The two gelatin standards are certified for C, N, and S isotopes. One example of their use is for isotope bioarchaeologists who may want to analyse collagen in ancient bones. The two new gelatin standards, cold-water fish gelatin (B2219) and bovine gelatin (B2222), add to the existing warm-water fish gelatin standard from Elemental (B2215) offer a broad spread of isotopic values. One additional unique factor of B2222 is that the cow which provided the bovine gelatin standard was primarily fed maize (a C4 type plant) its whole life.
The IRMS product range from Elemental Microanalysis provide compatible products for analysers such as the isoEArth+ from Sercon; full product details are in the newly published Micro & IRMS catalogue. Request a copy today.
More information online:
ilmt.co/PL/NA6A Novel reagents drive breakthroughs in Parkinson’s and sleep disorder research
In a recent blog post, AMSBIO sheds light on the ground-breaking strides achieved in Parkinson’s disease research, hypersomnia studies, and eco-friendly microbial ester production facilitated by their innovative BioPORTER®, Detachin™, and SoluLyse™ reagents. These reagents play a pivotal role in elevating research efficiency, precision, and reproducibility.
A collaborative initiative led by Dr Wenjing Wang at the University of Michigan and Dr Xiaobo Mao of Johns Hopkins University School of Medicine has propelled significant advancements in potential therapeutics for Parkinson’s disease. The utilisation of the BioPORTER® protein delivery reagent kit enabled seamless transduction of α-syn preformed fibrils to HEK293T cells, unravelling the relationship between α-syn aggregation and PFFNB2. BioPORTER® utilises biocompatible polymers to encapsulate and shield proteins during delivery, ensuring stability and activity for more accurate and reproducible outcomes.
Dr Andrew Jenkins and his team at the University of Saint Joseph are trailblazers in repurposing compounds to address sleep disorders, particularly hypersomnia. Employing Detachin™ Cell Detachment Solution, the researchers prepared cells for electrophysiological analysis, ensuring high cell viability and functionality through a reliable detachment process. This step is crucial in cell culture experiments, and Detachin™ minimises the risk of altered cell behaviour.
Microbial production of short-chain esters presents an eco-friendly alternative to chemical synthesis, yet challenges in low yields persist. Dr Arul M. Varman at Arizona State University and Dr Ryan Davis from Sandia National Laboratories harnessed the SoluLyse™ Bacterial Protein Extraction Reagent to streamline and expedite the extraction of high-quality protein from E. coli. This efficient formulation ensures optimal cell lysis without compromising protein integrity, addressing the challenge of low yields in microbial ester production.
Dr Maja Petkovic, Business Unit Manager at AMSBIO, emphasised the transformative impact of these reagents, stating: “Replacing basic life science reagents with products like BioPORTER®, Detachin™, and SoluLyse™ can lead to significant improvements in your research outcomes, offering enhanced performance and convenience for more reliable and reproducible results.”
Read the full blog post for comprehensive insights. For further details on innovative products for cellular and microbial research, contact AMSBIO or visit their website. More information online:
ilmt.co/PL/XOLA
62154pr@reply-direct.com Game-changing reagent kits to advance cell therapy development
Applied Cells introduces its ground-breaking MARS® Ingenuity™ Reagent kits, for fast and easy cell isolation. The newly launched product line has both Research Use Only (RUO) and Good Manufacturing Practice (GMP) grade reagents, tailored for application on Applied Cells’ proprietary MARS® Bar platform. This combination offers a comprehensive solution for high quality immunomagnetic cell isolation, advancing cell therapy development.
The amalgamation of high stability Ingenuity reagents with the high-capacity MARS Bar system presents a cost-effi cient cell separation solution ideal for developing CAR-T-based, monocyte-based CAR-macrophage therapies, and cancer vaccines. The kits contain biodegradable 50 nm superparamagnetic beads conjugated with monoclonal antibodies, alongside 4.5 μm superparamagnetic beads catering to various isolation needs such as CD4+, CD8+, CD14+, and CD3/28+ cell subsets.
Researchers can utilise the RUO reagent kits on the MARS® Bar Flex instrument for initial small-scale optimisation, seamlessly transitioning to GMP-grade reagents for large-scale cell manufacturing on the MARS Bar system, employing a single-use closed tubing set. The system facilitates highly effi cient immunomagnetic separation at rates of up to 6 ml/min, ensuring consistency in performance across all developmental phases.
The column-free design of the MARS Bar system enables direct cell isolation from an array of sample sizes and types, including leukopak, bone marrow, and whole peripheral blood, without additional washing steps. This streamlined process yields cell products of exceptional purity, viability, and recovery, expediting the time from research to market for novel therapies.
The integration of the MARS Bar system with Ingenuity reagents signifi cantly reduces time and capital expenditure, facilitating expedited therapy development and manufacturing scale-up. Researchers appreciate the convenience of direct cell isolation from blood samples, eliminating laborious processing steps and enhancing productivity with high inter-batch reproducibility.
The newly released MARS Ingenuity kits, developed in collaboration with T&L Biotechnology, offer a new option for cell therapy developers to accelerate the discovery of life-saving cell therapies. Committed to comprehensive customer support, Applied Cells plans to bring additional Ingenuity line products for cell therapy in the near future.
More information online:
ilmt.co/PL/ZRmY 62723pr@reply-direct.com
62474pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
